Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00291499
Other study ID # 03CH/Ct06
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date June 2005
Est. completion date August 2010

Study information

Verified date February 2021
Source IBSA Institut Biochimique SA
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of the present study is to investigate the effectiveness of Condrosulf® 800 mg tablets vs. placebo once a day for 6 months in the symptomatic treatment of finger joint osteoarthritis. Primary endpoints of the study are the evaluation of global spontaneous pain (Huskisson's Visual Analogue Scale: VAS) and the score of Dreiser's algo-functional index (FIHOA) during the treatment with the tested product, Condrosulf®, versus placebo.


Description:

The goal of the present study is to investigate the effectiveness of Condrosulf® 800 mg tablets vs. placebo once a day for 6 months in the symptomatic treatment of finger joint osteoarthritis in 160 randomised patients. Primary endpoints: Primary endpoints of the study are the evaluation of global spontaneous pain (Huskisson's Visual Analogue Scale: VAS) and the score of Dreiser's algo-functional index (FIHOA) during the treatment with the tested product, Condrosulf®, versus placebo. Secondary endpoints are: Efficacy evaluation: Global impression of efficacy expressed by the patient and the physician (VAS), Grip strength (measured manometrically); Morning stiffness duration; Consumption of Paracetamol; Tolerability (4-point verbal scale); Adverse Events occurring during the treatment period; Other parameters:Treatment compliance; Biological markers of arthritis


Recruitment information / eligibility

Status Completed
Enrollment 163
Est. completion date August 2010
Est. primary completion date December 2009
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: - Patients of either sex - Aged 40 and over - Outpatients - Patients fulfilling the American Congress of Rheumatology (ACR) criteria for the reporting of hand OA - Patients showing X-ray features of hand OA on at least two joints (2 IP and/or 1 IP and 1 TMC) of the dominant hand on standard plain radiographs (< 6 month). - Suffering from regular spontaneous pain on the dominant hand (VAS > or = 40 mm at inclusion time). - Showing a FIHOA score > or = 6. - Having had at least two painful flares in a finger joint during the previous 12 month. - Patients who have signed the written informed consent for their participation in the study - Patients able to understand and follow the protocol. - Patients with a satisfying health and nutritional status. - Female subjects of childbearing potential using, within three months prior to the inclusion in the study, a reliable form of contraception during the course of the study (oral contraceptive pill, intrauterine device or condoms) or female of non childbearing potential (hysterectomy, bilateral ovariectomy or tubal section/ligation). - Female subjects of childbearing potential with a negative urinary pregnancy test before the inclusion in the study. Exclusion Criteria: - Inflammatory joint disease of other origin - Septic arthritis - Chronic inflammatory joint disease - Previous articular fracture of the concerned articulations - Use of analgesic therapy for other indications - Receiving oral corticosteroids - Mono-articular posttraumatic OA of the finger - Planning surgery of the hands in the following 6 months - Patients suffering or having suffered from secondary osteoarthritis after one of the following diseases: - Infectious arthritis - Acromegaly - Ochronosis - Hemachromatosis - Gout - Wilson's disease - Chondrocalcinosis - Paget's disease - Osteochondrosis - Mutation of collagen - Genetic problems (for ex. hypermobility) - Previous joint fracture - Arthropathies of different aetiologies - Algodystrophy (M. Sudeck) - Congenital abnormalities - Recurrent pseudogout - Major dysplasias - Intra-articular injection in a hand joint from less than 3 months - Basic treatment of arthritis with symptom-modifying agents (chondroitin sulfate, glucosamine sulfate, diacerhein, hyaluronic acid) in the last 3 months - Articular lavage in the last 3 months - Treatment with corticoids, by any administration route during the last month - Patient suffering from frequent asthma crises - Physiotherapy, re-education, alternative medicine (mesotherapy, acupuncture) on the hands foreseeable in the next year - Serious organic diseases: heart failure, renal or hepatic insufficiency, blood dyscrasia, serious infection - Participation in other clinical trials in the two months preceding the study - Known or ascertained hypersensitivity to the active ingredient of the tested drug. - Patients refusing to sign the written informed consent form - Patients who do not co-operate, not respecting the protocol requirements - Pregnant or lactating women

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Chondroitin 4&6 sulfate (Condrosulf)
800 mg/day for 6 months
Other:
Placebo
800 mg placebo/day for 6 months

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
IBSA Institut Biochimique SA

References & Publications (18)

Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D, Brandt K, Brown C, Cooke TD, Daniel W, Gray R, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum. 1990 Nov;33(11):1601-10. — View Citation

Bourgeois P, Chales G, Dehais J, Delcambre B, Kuntz JL, Rozenberg S. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 x 400 mg/day vs placebo. Osteoarthritis Cartilage. 1998 May;6 Suppl A:25-30. — View Citation

Bucsi L, Poór G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage. 1998 May;6 Suppl A:31-6. — View Citation

Cicuttini FM, Spector TD. Osteoarthritis in the aged. Epidemiological issues and optimal management. Drugs Aging. 1995 May;6(5):409-20. Review. — View Citation

Conte A, de Bernardi M, Palmieri L, Lualdi P, Mautone G, Ronca G. Metabolic fate of exogenous chondroitin sulfate in man. Arzneimittelforschung. 1991 Jul;41(7):768-72. — View Citation

Dreiser RL, Maheu E, Guillou GB, Caspard H, Grouin JM. Validation of an algofunctional index for osteoarthritis of the hand. Rev Rhum Engl Ed. 1995 Jun;62(6 Suppl 1):43S-53S. — View Citation

Howell DS, Altman RD. Cartilage repair and conservation in osteoarthritis. A brief review of some experimental approaches to chondroprotection. Rheum Dis Clin North Am. 1993 Aug;19(3):713-24. Review. — View Citation

Lequesne M. [Symptomatic slow-action anti-arthritic agents: a new therapeutic concept?]. Rev Rhum Ed Fr. 1994 Feb;61(2):75-9. French. — View Citation

Mazières B, Loyau G, Menkès CJ, Valat JP, Dreiser RL, Charlot J, Masounabe-Puyanne A. [Chondroitin sulfate in the treatment of gonarthrosis and coxarthrosis. 5-months result of a multicenter double-blind controlled prospective study using placebo]. Rev Rhum Mal Osteoartic. 1992 Jul-Sep;59(7-8):466-72. French. — View Citation

Michel BA, Stucki G, Frey D, De Vathaire F, Vignon E, Bruehlmann P, Uebelhart D. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum. 2005 Mar;52(3):779-86. — View Citation

Morreale P, Manopulo R, Galati M, Boccanera L, Saponati G, Bocchi L. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol. 1996 Aug;23(8):1385-91. — View Citation

Ronca F, Palmieri L, Panicucci P, Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage. 1998 May;6 Suppl A:14-21. — View Citation

Uebelhart D, Malaise M, Marcolongo R, de Vathaire F, Piperno M, Mailleux E, Fioravanti A, Matoso L, Vignon E. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage. 2004 Apr;12(4):269-76. Erratum in: Osteoarthritis Cartilage. 2007 Aug;15(8):979. DeVathaire, Florent [corrected to de Vathaire, Florent]. — View Citation

Uebelhart D, Thonar EJ, Delmas PD, Chantraine A, Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage. 1998 May;6 Suppl A:39-46. — View Citation

Uebelhart D, Thonar EJ, Zhang J, Williams JM. Protective effect of exogenous chondroitin 4,6-sulfate in the acute degradation of articular cartilage in the rabbit. Osteoarthritis Cartilage. 1998 May;6 Suppl A:6-13. — View Citation

Verbruggen G, Goemaere S, Veys EM. Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthritis Cartilage. 1998 May;6 Suppl A:37-8. — View Citation

Verbruggen G, Goemaere S, Veys EM. Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheumatol. 2002 Jun;21(3):231-43. — View Citation

Volpi N. Oral bioavailability of chondroitin sulfate (Condrosulf) and its constituents in healthy male volunteers. Osteoarthritis Cartilage. 2002 Oct;10(10):768-77. — View Citation

* Note: There are 18 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Global Spontaneous Pain Intensity of Target Hand Intensity of global spontaneous pain is evaluated by the patient himself on a Huskisson's visual analogue scale (VAS) of 100 mm. 0=no pain 100=max pain Change calculated as difference between Month 6 value and baseline value target hand is defined as the patient's most symptomatic hand or, when both hands were equally painful, the patient's dominant hand. 6 months
Primary Change in Functional Index for Hand Osteoarthritis Dreiser's Score (FIHOA) in the Target Hand Functional Index for Hand Osteoarthritis (Dreiser's Index). Range 0-30 Patients reported the severity of their symptoms by answering a set of 10 questions. Severity was rated on a numerical scale (0 = possible without difficulty, 1 = possible with slight difficulty, 2 =possible with great difficulty, and 3 = impossible), being 30 points the worst possible pain score.
Change calculated as difference between the month 6 value and baseline value
Target hand defined as the patient's most symptomatic hand or, when both hands were equally painful, the patient's dominant hand
6 month
Secondary Investigator Global Evaluation on Efficacy Global impression of the efficacy judged by the Investigators at month 6 by means of a visual analogue scale from 0 (no efficacy) to 100 mm (very good efficacy) 6 months
Secondary Change in Grip Strength Grip strength determined on both hands using a Jamar dynamometer.Patients were required to grip the dynamometer handle and squeeze as hard as possible according to their individual pain limits. The right hand grip was measured first, then the left; this procedure was performed 3 times. The mean value of these 3 measurements was recorded.
Change calculated as difference between the month 6 value and baseline value
6 months
Secondary Change in Morning Stiffness Duration Change in morning stiffness duration calculated as the difference between the month 6 value and the baseline value 6 months
Secondary Consumption of Paracetamol Total consumption (between ^baseline and month 6) of paracetamol (500 mg tablets) reported by the patients on a daily diary 6 months
See also
  Status Clinical Trial Phase
Completed NCT02542592 - Effect of Methylprednisolone on Immune Signaling in Hip-arthroplasty Patients Phase 2/Phase 3
Completed NCT02445898 - Effect of Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Hip-arthroplasty Patients Phase 2/Phase 3
Completed NCT02910830 - Osteoarthritis Relationships and Tobacco " Ancillary Study Khoala " N/A
Completed NCT01443975 - Clinical Evaluation on the Use of the X-pander Device N/A
Completed NCT01603017 - Nuclear Magnetic Resonance Therapy in Knee Osteoarthrosis N/A
Completed NCT02222740 - A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Patients With Osteoarthritis Pain Phase 2
Completed NCT00860873 - Effectiveness of Glucosamine + Chondroitin in Osteoarthrosis Phase 3
Recruiting NCT02923310 - Evaluation of Two Types of PRP in Knee Osteoarthritis Phase 1/Phase 2
Active, not recruiting NCT02518269 - A 3-Arm Study on G7 Acetabular Cup With Echo BiMetric Stem in Total Hip Arthroplasty N/A
Completed NCT03093038 - Early Stability of the Delta-TT Cup With Polyethylene Insert Versus a Ceramic Insert. A RSA Study. N/A
Completed NCT02967874 - Autologous Adipose-Derived Stromal Vascular Fraction Cells for Osteoarthritis Treatment Phase 1/Phase 2
Withdrawn NCT02341079 - Intraoperative Liposomal Bupivacaine Injection in Primary Total Knee Arthroplasty Phase 2/Phase 3
Recruiting NCT05882227 - Nursing Intervention for the Reduction of Anxiety During the Process of Primary Total Hip Arthroplasty Within the Optimized Recovery Program. N/A
Completed NCT05697952 - E1K Intra Articular(IA) Treatment for Knee Osteoarthritis Phase 2
Completed NCT01940692 - Topical and Intravenous Administration of TXA Are Equally Effective in DAA THA Phase 2
Completed NCT02071745 - Navigated Total Knee Arthroplasty, the Correlation to CT Scans and Clinical Results N/A
Completed NCT02332616 - Effect of Methylprednisolone on Complement Activation in Patients Undergoing Total Knee-arthroplasty Phase 3
Completed NCT02332629 - Effect of Methylprednisolone on Endothelial Function in Patients Undergoing Total Knee-arthroplasty Phase 3
Completed NCT02319343 - Effect of Methylprednisolone on Quadriceps Muscle Function in Patients Undergoing Total Knee-arthroplasty Phase 3
Completed NCT02332603 - Effect of Methylprednisolone on Glucose Homeostasis in Patients Undergoing Total Hip- and Knee-arthroplasty Phase 3